Skip to main content

Type 2 diabetes


05-06-2020 | Genetics | Highlight | News

Genetic markers of type 2 diabetes risk in East Asian people uncovered

A major genetic analysis sheds light on the similarities and differences in type 2 diabetes pathogenesis between people of East Asian and European origin.

05-05-2020 | Prediabetes | Highlight | News

Prediabetes marks increased vascular risk

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

04-24-2020 | Semaglutide | Highlight | News

PIONEER 9, 10 confirm oral semaglutide efficacy in Japanese population

Results of the PIONEER 9 and 10 trials show that oral semaglutide is efficacious in Japanese people with type 2 diabetes.

04-16-2020 | Nephropathy | Highlight | News

Hypoglycemia risk with even mild renal dysfunction in real-world practice

A large observational study reveals a strong link between reduced kidney function and increased incidence of hypoglycemia in adults with diabetes in routine clinical practice.

04-09-2020 | Metformin | Highlight | News

Preoperative metformin use associated with better outcomes after major surgery

People with type 2 diabetes who are treated with metformin prior to undergoing major surgical interventions may have better postoperative outcomes than those without exposure to the drug, researchers report.

04-06-2020 | Heart failure | Highlight | News

Exercise better than diet to combat early heart changes in type 2 diabetes

The results of a small randomized trial suggest exercise is more helpful than diet for combating early cardiac dysfunction associated with type 2 diabetes, although both may be beneficial.

03-31-2020 | SGLT2 inhibitors | Highlight | News

Cardioprotective benefits of dapagliflozin extend beyond people with diabetes

Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.

03-24-2020 | Older adults | Highlight | News

Diabetes medication changes at hospital discharge of older adults often not beneficial

Older adults with type 2 diabetes often receive diabetes medication adjustments at hospital discharge that may be of little or no benefit, study results suggest.

03-11-2020 | Liraglutide (obesity) | Highlight | News

Liraglutide 3.0 mg boosts weight loss in insulin-dependent type 2 diabetes

Adding liraglutide 3.0 mg to intensive behavioral therapy increases weight loss in overweight or obese people with insulin-treated type 2 diabetes, results of the phase 3 SCALE Insulin trial show.

02-26-2020 | Coronary artery disease | Highlight | News

Urgent action needed to improve dysglycemia screening in patients with heart disease

More than half of people with coronary artery disease have impaired glucose tolerance, yet many are unaware of this or are undertreated despite knowledge of their condition, results of the EUROASPIRE V survey show.

02-24-2020 | Risk factors | Highlight | News

Diagnosis age enhances predictive power of family diabetes history

The risk associated with a family history of type 2 diabetes is highest for people whose near relatives were diagnosed with the condition at a young age, show registry data.

02-10-2020 | Latent autoimmune diabetes of adulthood | Highlight | News

‘Early therapeutic window’ highlighted for LADA

Optimal glycemic control during the first years after a latent autoimmune diabetes of adulthood diagnosis could prevent people’s microvascular complication risk from equaling that seen in those with type 2 diabetes, shows an analysis of the UKPDS.

02-04-2020 | Glycemic control | Highlight | News

Haptoglobin genotype may dictate success of intensive glucose control

The benefits and harms of intensive glucose control in people with type 2 diabetes may depend on which form of haptoglobin they have, shows an analysis of the ACCORD trial.

01-22-2020 | Insulin glargine | Highlight | News

About 50% attain type 2 glycemic targets with glargine 300 in real-world

Initiating insulin glargine 300 U/mL could help half of those patients whose type 2 diabetes is inadequately controlled with oral antidiabetic medication to achieve their personal glycemic target within a year, real-world data suggest.

01-13-2020 | SGLT2 inhibitors | Highlight | News

Lower gout risk with SGLT2 inhibitors vs GLP-1 receptor agonists

People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.

12-20-2019 | SGLT2 inhibitors | Highlight | News

CVD-REAL 3: Renal benefits of SGLT2 inhibitors confirmed in real-world study

Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.

12-12-2019 | Diabetes self-management | Highlight | News

‘Upskilling’ healthcare providers could address concerns of people with diabetes

A large survey has uncovered a number of issues that particularly frustrate people with diabetes during their interactions with their healthcare providers.

12-10-2019 | Nephropathy | Highlight | News

Nonalbuminuric CKD risks confirmed in type 2 diabetes

People with type 2 diabetes and reduced kidney function in the absence of albuminuria have an increased risk for mortality and major adverse cardiovascular events, despite a low risk for end-stage renal disease, research shows.

11-29-2019 | Older adults | Highlight | News

Prediabetes not an immediate mortality concern in older adults

Prediabetes has no effect on the short-term mortality risk of older adults, suggests an analysis of the Atherosclerosis Risk in Communities study.

11-27-2019 | Metabolic surgery | Highlight | News

Preoperative diabetes duration may affect remission rates after bariatric surgery

Swedish research suggests that determining type 2 diabetes duration prior to bariatric surgery could help prioritize those patients most likely to achieve diabetes remission.

Image Credits